II. Indications
- Gram Negative Infections
- Cystic Fibrosis respiratory exacerbation
- Tuberculosis (second-line agent)
III. Mechanism
- See Aminoglycoside
- Amikacin is derived from Kanamycin
IV. Dosing
-
Gram Negative Infections in Adults and Children (FDA Approved dosing)
- Give 15 mg/kg/day (max 1500 mg/day) IM or IV divided every 8 to 12 hours
- Once daily 15 mg/kg dose is used off-label
-
Gram Negative Infections in Newborns (age <1 month)
- Give 10 mg/kg IM or IV load, then 7.5 mg/kg IM or IV every 12 hours
-
Cystic Fibrosis Respiratory Exacerbation
- Give 30 to 35 mg/kg IV every 24 hours and adjust dose based on levels
- Target peak 80 to 120 mcg/ml
- Target trough <10 mcg/ml
V. Adverse Effects
- See Aminoglycoside
-
Aminoglycosides are associated with risk of Ototoxicity and nephrotoxicity (FDA black box warning)
- See Aminoglycoside for risk factors
VI. Safety
- Pregnancy Category D
- Considered safe in Lactation
VII. Resources
- Amikacin Injection Solution (DailyMed)
VIII. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- Sizar (2023) Amikacin, StatPearls, Treasure Island, FL
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI_NCI-GLOSS) | An antibiotic drug used to treat infection. It belongs to the family of drugs called aminoglycoside antibiotics. |
Definition (NCI) | A broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically locking 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and , misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. |
Definition (MSH) | A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics. |
Concepts | Antibiotic (T195) , Carbohydrate (T118) |
MSH | D000583 |
SnomedCT | 391753009, 387266001, 48836000 |
LNC | LP15005-9, MTHU002886 |
English | Amikacin, D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-, amikacin, Amikacin [Chemical/Ingredient], Amikacin - chemical (substance), Amikacin - chemical, AMIKACIN, Amikacin (product), Amikacin (substance), AMIKA |
Swedish | Amikacin |
Czech | amikacin |
Finnish | Amikasiini |
Russian | AMIKATSIN, BB-K8, АМИКАЦИН |
Japanese | アミカシン |
Spanish | amikacina (sustancia), amicacina (sustancia), amicacina, amikacina (producto), amikacina, Amicacina |
Polish | Amikacyna |
French | Amikacine |
German | Amikacin |
Italian | Amikacina |
Portuguese | Amicacina |
Ontology: Amikacin Sulfate (C0002501)
Definition (NCI) | The sulfate salt of amikacin, a broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically in contact with 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. |
Concepts | Antibiotic (T195) , Carbohydrate (T118) |
MSH | D000583 |
SnomedCT | 391754003, 1269009 |
English | Sulfate, Amikacin, amikacin sulfate, amikacin sulfate (medication), AMIKACIN SULFATE, Amikacin Sulfate [Chemical/Ingredient], amikacin sulphate, Amikacin sulphate - chemical (substance), Amikacin sulphate - chemical, Amikacin sulfate, Amikacin sulfate (substance), Amikacin sulphate, Amikacin Sulfate |
French | Sulfate d'amikacine, Amikacin sulfate |
Spanish | amicacina sulfato (sustancia), amicacina sulfato, sulfato de amikacina, sulfato de amikacina (sustancia), sulfato de amicacina |